Background illustration for clinical trials search

Paid Clinical Trials Tennessee

Discover 1,846 paid clinical trials in Tennessee. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 1,846

Featured

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

for

Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer,

Location: Providence RI, Teaneck NJ, Syracuse NY, Fairfax VA,

Sponsor: AbbVie

Sex: Female

Age: 18+

Code: NCT07024784

Phase2, Recruiting

Featured

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)

for

Diabetic Macular Edema

Location: Philadelphia PA, Baltimore MD, Lynchburg VA, Erie PA,

Sponsor: Genentech, Inc.

Sex: All

Age: 18+

Code: NCT07425522

Phase1, Recruiting

Featured

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

for

Parkinson's Disease

Location: Boston MA, New Haven CT, New York NY, Commack NY,

Sponsor: Hoffmann-La Roche

Sex: All

Age: 50 - 70+

Code: NCT07174310

Phase3, Recruiting

Featured

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

for

Obesity, Overweight

Location: Morehead City NC, Newport News VA, New Bern NC,

Sponsor: AbbVie

Sex: All

Age: 18 - 70+

Code: NCT07752979

Phase2, Recruiting

Featured

A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease

for

Alzheimer's Disease

Location: Watertown MA, Wellington FL, Stuart FL, Winter Park FL,

Sponsor: AbbVie

Sex: All

Age: 50 - 70+

Code: NCT07599670

Phase1, Phase2, Recruiting

Featured

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

for

Acute Myeloid Leukemia

Location: Valhalla NY, Atlanta GA, Nashville TN, Dallas TX,

Sponsor: AbbVie

Sex: All

Age: 0 - 17

Code: NCT07306832

Phase1, Recruiting

Featured

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

for

Alzheimers Disease

Location: Halifax, Boston MA, Watertown MA, Newton MA,

Sponsor: Hoffmann-La Roche

Sex: All

Age: 50 - 70+

Code: NCT07177352

Phase3, Recruiting

Featured

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

for

Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer

Location: Rimouski, Boston MA, Worcester MA, Hartford CT, Quebec,

Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06793215

Phase3, Recruiting

Featured

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

for

HER2-positive Breast Cancer

Location: Norwich CT, Shirley NY, Quebec, Stony Brook NY,

Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT07413939

Phase2, Phase3, Recruiting

Featured

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

for

Breast Cancer

Location: Boston MA, East Patchogue NY, The Bronx NY,

Sponsor: Genentech, Inc.

Sex: All

Age: 18+

Code: NCT07100106

Phase1, Phase2, Recruiting

Featured

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

for

Breast Cancer

Location: Montreal, Morgantown WV, Toronto, Germantown TN,

Sponsor: Hoffmann-La Roche

Sex: Female

Age: 18+

Code: NCT07054190

Phase2, Recruiting

Featured

A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events

for

Atherosclerosis

Location: New Haven CT, North Massapequa NY, Chapel Hill NC,

Sponsor: Genentech, Inc.

Sex: All

Age: 18+

Code: NCT07448038

Phase2, Recruiting

Featured

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

for

Breast Cancer

Location: Moncton, Shirley NY, The Bronx NY, New York NY,

Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06790693

Phase3, Recruiting

Featured

Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

for

Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma

Location: Boston MA, Albany NY, Virginia Beach VA,

Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06806033

Phase2, Recruiting

Featured

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

for

Chronic Migraine

Location: Nashua NH, Philadelphia PA, Miami FL, Weston FL,

Sponsor: AbbVie

Sex: All

Age: 12 - 17

Code: NCT06810505

Phase3, Recruiting

Featured

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

for

Migraine

Location: Nashua NH, Stamford CT, Morristown NJ, Philadelphia PA,

Sponsor: AbbVie

Sex: All

Age: 6 - 17

Code: NCT05125302

Phase3, Recruiting

Featured

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

for

Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer

Location: New York NY, Philadelphia PA, Nashville TN, Chicago IL,

Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06858813

Phase1, Recruiting

Featured

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

for

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis,

Location: Burlington MA, East Greenwich RI, Carmel NY,

Sponsor: 89bio, Inc.

Sex: All

Age: 18 - 70+

Code: NCT06318169

Phase3, Recruiting

Featured

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

for

Episodic Migraine

Location: Morristown NJ, Philadelphia PA, Franklin VA, Miami FL,

Sponsor: AbbVie

Sex: All

Age: 6 - 17

Code: NCT05711394

Phase3, Recruiting

Featured

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

for

Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis,

Location: Burlington MA, East Greenwich RI, Framingham MA,

Sponsor: 89bio, Inc.

Sex: All

Age: 18 - 70+

Code: NCT06419374

Phase3, Recruiting

Popular cities in Tennessee

Murfreesboro Chattanooga Knoxville Nashville Memphis

Paid Clinical Trials Tennessee

Filter results

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease

Interested in new trials?

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

Popular cities in Tennessee